These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21191005)

  • 1. Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.
    Abel K; Martinez J; Yue Y; Lacey SF; Wang Z; Strelow L; Dasgupta A; Li Z; Schmidt KA; Oxford KL; Assaf B; Longmate JA; Diamond DJ; Barry PA
    J Virol; 2011 Mar; 85(6):2878-90. PubMed ID: 21191005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.
    Abel K; Strelow L; Yue Y; Eberhardt MK; Schmidt KA; Barry PA
    Vaccine; 2008 Nov; 26(47):6013-25. PubMed ID: 18760319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.
    Wussow F; Yue Y; Martinez J; Deere JD; Longmate J; Herrmann A; Barry PA; Diamond DJ
    J Virol; 2013 Feb; 87(3):1322-32. PubMed ID: 23152525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploitation of Interleukin-10 (IL-10) Signaling Pathways: Alternate Roles of Viral and Cellular IL-10 in Rhesus Cytomegalovirus Infection.
    Eberhardt MK; Deshpande A; Fike J; Short R; Schmidt KA; Blozis SA; Walter MR; Barry PA
    J Virol; 2016 Nov; 90(21):9920-9930. PubMed ID: 27558431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of Wild-Type-Like Rhesus Cytomegalovirus Strains following Oral Exposure of Immune-Competent Rhesus Macaques.
    Yue Y; Chang WLW; Li J; Nguyen N; Schmidt KA; Dormitzer PR; Yang X; Barry PA
    J Virol; 2022 Feb; 96(3):e0165321. PubMed ID: 34788083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques.
    Yue Y; Kaur A; Eberhardt MK; Kassis N; Zhou SS; Tarantal AF; Barry PA
    J Virol; 2007 Feb; 81(3):1095-109. PubMed ID: 17108040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques.
    Yue Y; Wang Z; Abel K; Li J; Strelow L; Mandarino A; Eberhardt MK; Schmidt KA; Diamond DJ; Barry PA
    Med Microbiol Immunol; 2008 Jun; 197(2):117-23. PubMed ID: 18196272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model.
    Valencia S; Gill RB; Dowdell KC; Wang Y; Hornung R; Bowman JJ; Lacayo JC; Cohen JI
    Vaccine; 2019 Jan; 37(2):333-342. PubMed ID: 30522906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open reading frames carried on UL/b' are implicated in shedding and horizontal transmission of rhesus cytomegalovirus in rhesus monkeys.
    Oxford KL; Strelow L; Yue Y; Chang WL; Schmidt KA; Diamond DJ; Barry PA
    J Virol; 2011 May; 85(10):5105-14. PubMed ID: 21389128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of postnatal rhesus cytomegalovirus shedding by dams and acquisition by infant rhesus monkeys.
    Kaur A; Itell HL; Ehlinger EP; Varner V; Gantt S; Permar SR
    PLoS One; 2018; 13(10):e0206330. PubMed ID: 30356332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity.
    Deere JD; Chang WLW; Villalobos A; Schmidt KA; Deshpande A; Castillo LD; Fike J; Walter MR; Barry PA; Hartigan-O'Connor DJ
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):13036-13041. PubMed ID: 31189602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination against a virus-encoded cytokine significantly restricts viral challenge.
    Eberhardt MK; Deshpande A; Chang WL; Barthold SW; Walter MR; Barry PA
    J Virol; 2013 Nov; 87(21):11323-31. PubMed ID: 23946461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65).
    Yue Y; Kaur A; Zhou SS; Barry PA
    J Gen Virol; 2006 Apr; 87(Pt 4):777-787. PubMed ID: 16528025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Horizontal Transmission of Cytomegalovirus in a Rhesus Model Despite High-Level, Vaccine-Elicited Neutralizing Antibody and T-Cell Responses.
    Li J; Wellnitz S; Chi XS; Yue Y; Schmidt KA; Nguyen N; Chen W; Yurgelonis I; Rojas E; Liu Y; Loschko J; Pollozi E; Matsuka YV; Needle E; Vidunas E; Donald RGK; Moran J; Jansen KU; Dormitzer PR; Barry PA; Yang X
    J Infect Dis; 2022 Sep; 226(4):585-594. PubMed ID: 35413121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited dissemination and shedding of the UL128 complex-intact, UL/b'-defective rhesus cytomegalovirus strain 180.92.
    Assaf BT; Mansfield KG; Strelow L; Westmoreland SV; Barry PA; Kaur A
    J Virol; 2014 Aug; 88(16):9310-20. PubMed ID: 24899204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
    Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
    Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
    Lilja AE; Mason PW
    Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhesus and human cytomegalovirus glycoprotein L are required for infection and cell-to-cell spread of virus but cannot complement each other.
    Bowman JJ; Lacayo JC; Burbelo P; Fischer ER; Cohen JI
    J Virol; 2011 Mar; 85(5):2089-99. PubMed ID: 21191007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.
    Webster H; Valencia S; Kumar A; Chan C; Dennis M; Roark H; Woods A; John S; Carfi A; Permar SR
    Vaccine; 2021 Sep; 39(38):5358-5367. PubMed ID: 34393017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.